Literature DB >> 14605276

Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia.

Robert J Nijveldt1, Tom Teerlink, Coen van Guldener, Hubert A Prins, Antonie A van Lambalgen, Coen D A Stehouwer, Jan A Rauwerda, Paul A M van Leeuwen.   

Abstract

BACKGROUND: Asymmetrical dimethylarginine (ADMA) is capable of inhibiting nitric oxide synthase enzymes, whereas symmetrical dimethylarginine (SDMA) competes with arginine transport. The potential role of inflammation in the metabolism of ADMA has been elucidated in an in vitro model using tumour necrosis factor-alpha, resulting in a decreased activity of the ADMA-degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH). The kidney probably plays a crucial role in the metabolism of ADMA by both urinary excretion and degradation by DDAH. We aimed to further elucidate the role of the kidney in a rat model under basal conditions and during endotoxaemia.
METHODS: Twenty-five male Wistar rats weighing 275-300 g were used for this study. The combination of arteriovenous concentration differences and kidney blood flow allowed calculation of net organ fluxes. Blood flow was measured using radiolabelled microspheres according to the reference sample method. Concentrations of ADMA, SDMA and arginine were measured by high-performance liquid chromatography.
RESULTS: The kidney showed net uptake of both ADMA and SDMA and fractional extraction rates were 35% and 31%, respectively. Endotoxaemia resulted in a lower systemic ADMA concentration (P = 0.01), which was not explained by an increased net renal uptake. Systemic SDMA concentrations increased during endotoxaemia (P = 0.007), which was accompanied by increased creatinine concentrations.
CONCLUSIONS: The rat kidney plays a crucial role in the regulation of concentrations of dimethylarginines, as both ADMA and SDMA were eliminated from the systemic circulation in substantial amounts. Furthermore, evidence for the role of endotoxaemia in the metabolism of dimethylarginines was obtained as plasma levels of ADMA were significantly lower in endotoxaemic rats.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605276     DOI: 10.1093/ndt/gfg452

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  29 in total

Review 1.  Sexual dimorphism in the aging kidney: differences in the nitric oxide system.

Authors:  Chris Baylis
Journal:  Nat Rev Nephrol       Date:  2009-06-02       Impact factor: 28.314

Review 2.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

Review 3.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

4.  Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors.

Authors:  Kaan Gökçen; Hakan Kılıçarslan; Burhan Coşkun; Alparslan Ersoy; Onur Kaygısız; Yakup Kordan
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

5.  Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.

Authors:  Scott L Weiss; Shannon Haymond; Hantamalala Ralay Ranaivo; Deli Wang; Victor R De Jesus; Donald H Chace; Mark S Wainwright
Journal:  Pediatr Crit Care Med       Date:  2012-07       Impact factor: 3.624

6.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

7.  Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome.

Authors:  Serkan Nural; Ersin Günay; Bilal Halici; Sefa Celik; Mehmet Ünlü
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 8.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

Review 9.  Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Frans G M Russel; Peter Pickkers
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 10.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.